Pay in 4 interest-free payments of $6.27 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
FMT trials MIMic (NCT03772899) is a phase 1 trial 23 enrolling patients with unresectable or metastatic cutaneous melanoma measurable disease as per RECIST v.1.1 criteria with no previous anti-PD-1 treatment who underwent FMT and were treated with anti-PD-1 (either pembrolizumab or nivolumab)
Additional Benefits:Relieves nausea and headaches
Supplied as a co-lyophilized blend of 5mg each at analytical purity
Are recovering from an illness or surgery and need an extra health boost
or are not appropriately licensed
Dr James products usually simplify your skin care to make it easy for you to care for your skin on a daily basis
US$ 28.38
US$ 21.85
US$ 26.25
